Other languages Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Market Closed - OTC Markets Other stock markets 03:57:37 2024-05-03 pm EDT			5-day change	1st Jan Change
0.193 ^USD	+0.91%		-2.72%	+101.15%

Apr. 18	Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose	CI
Apr. 16	Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose	Apr. 18
Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	Apr. 16
Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer	Apr. 16
Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting	Apr. 11
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Provectus Biopharmaceuticals, Inc. Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium	Mar. 27
Provectus Biopharmaceuticals, Inc. Announces Management Changes	Mar. 26
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma	Nov. 15
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Metastatic Uveal Melanoma	Nov. 13
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas	23-06-28
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10(R) and Keytruda(R) for First-Line Stage III Melanoma at Melanoma Bridge 2022	22-12-01
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09
Provectus Biopharmaceuticals Inc. Establishes Research Collaboration with University of Texas Medical Branch At Galveston	22-09-29
Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections	22-09-21
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair	22-07-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Other languages

Filters